Dongmei Liu1, Binbin Zhou2, Zhen Li3, Zhuojun Zhang1, Xiaojuan Dai1, Zongfei Ji1, Huiyong Chen1, Ying Sun1, Lindi Jiang4. 1. Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, 200023, China. 2. Department of Rheumatology, Xiamen Hospital, Zhongshan Hospital, Fudan University, Xiamen, China. 3. Clinical Research Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China. 4. Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, 200023, China. zsh-rheum@hotmail.com.
Abstract
OBJECTIVES: Benzbromarone and febuxostat use different mechanisms to reduce serum urate. However, the effectiveness of benzbromarone versus febuxostat in reducing serum urate in gouty patients classified with different types of hyperuricaemia remains unclear. METHOD: In this retrospective study from January 1, 2018, to September 30, 2020, subjects were identified if they were newly treated with benzbromarone 25 mg daily or febuxostat 20 mg daily. The subjects were classified into four types according to their 24-h urinary uric acid and fractional excretion of uric acid. The baseline data and follow-up information after 28 ± 3 days of treatment were collected. RESULTS: Seventy-three subjects with gout were finally enrolled. Among them, 50 were treated with benzbromarone. The percent changes in serum urate from the baseline were - 33.71 ± 13.59% and - 29.45 ± 10.62% in the benzbromarone and febuxostat group, respectively, without a significant difference between the groups (P = 0.188). No differences were found between the groups in subjects classified as the renal underexcretion type, combined type, or "normal" type. In patients with eGFR ≥ 70 mL/min/1.73 m2, the rate of serum urate lowering was higher in those treated with benzbromarone than in those treated with febuxostat. Febuxostat treatment significantly lowered serum creatinine from the baseline (P = 0.001). CONCLUSIONS: Benzbromarone 25 mg daily and febuxostat 20 mg daily may have comparable effectiveness in lowering the serum urate among different types of hyperuricaemia. Benzbromarone was more effective than febuxostat in lowering serum urate in subjects with eGFR ≥ 70 mL/min/1.73 m2, while febuxostat had a renal protective effect. Key Points • Benzbromarone 25 mg daily and febuxostat 20 mg daily may have comparable effectiveness in lowering the serum urate in patients with different types of hyperuricaemia. • Benzbromarone 25 mg daily was more effective than febuxostat 20 mg daily in lowering serum urate in subjects with eGFR ≥ 70 mL/min/1.73 m2. • Febuxostat had a renal protective effect after about 1 month treatment.
OBJECTIVES: Benzbromarone and febuxostat use different mechanisms to reduce serum urate. However, the effectiveness of benzbromarone versus febuxostat in reducing serum urate in gouty patients classified with different types of hyperuricaemia remains unclear. METHOD: In this retrospective study from January 1, 2018, to September 30, 2020, subjects were identified if they were newly treated with benzbromarone 25 mg daily or febuxostat 20 mg daily. The subjects were classified into four types according to their 24-h urinary uric acid and fractional excretion of uric acid. The baseline data and follow-up information after 28 ± 3 days of treatment were collected. RESULTS: Seventy-three subjects with gout were finally enrolled. Among them, 50 were treated with benzbromarone. The percent changes in serum urate from the baseline were - 33.71 ± 13.59% and - 29.45 ± 10.62% in the benzbromarone and febuxostat group, respectively, without a significant difference between the groups (P = 0.188). No differences were found between the groups in subjects classified as the renal underexcretion type, combined type, or "normal" type. In patients with eGFR ≥ 70 mL/min/1.73 m2, the rate of serum urate lowering was higher in those treated with benzbromarone than in those treated with febuxostat. Febuxostat treatment significantly lowered serum creatinine from the baseline (P = 0.001). CONCLUSIONS: Benzbromarone 25 mg daily and febuxostat 20 mg daily may have comparable effectiveness in lowering the serum urate among different types of hyperuricaemia. Benzbromarone was more effective than febuxostat in lowering serum urate in subjects with eGFR ≥ 70 mL/min/1.73 m2, while febuxostat had a renal protective effect. Key Points • Benzbromarone 25 mg daily and febuxostat 20 mg daily may have comparable effectiveness in lowering the serum urate in patients with different types of hyperuricaemia. • Benzbromarone 25 mg daily was more effective than febuxostat 20 mg daily in lowering serum urate in subjects with eGFR ≥ 70 mL/min/1.73 m2. • Febuxostat had a renal protective effect after about 1 month treatment.
Authors: L K Stamp; J Haslett; C Frampton; D White; D Gardner; S Stebbings; G Taylor; R Grainger; R Kumar; S Kumar; T Kain; D Porter; M Corkill; A Cathro; S Metcalfe; J Wyeth; N Dalbeth Journal: Intern Med J Date: 2016-09 Impact factor: 2.048
Authors: Valderilio Feijó Azevedo; Igor Age Kos; Ana Beatriz Vargas-Santos; Geraldo da Rocha Castelar Pinheiro; Eduardo Dos Santos Paiva Journal: Adv Rheumatol Date: 2019-08-07
Authors: Abbas Dehghan; Anna Köttgen; Qiong Yang; Shih-Jen Hwang; Wh Linda Kao; Fernando Rivadeneira; Eric Boerwinkle; Daniel Levy; Albert Hofman; Brad C Astor; Emelia J Benjamin; Cornelia M van Duijn; Jacqueline C Witteman; Josef Coresh; Caroline S Fox Journal: Lancet Date: 2008-10-01 Impact factor: 79.321
Authors: Kazi Mirajul Hoque; Eryn E Dixon; Raychel M Lewis; Jordyn Allan; Gregory D Gamble; Amanda J Phipps-Green; Victoria L Halperin Kuhns; Anne M Horne; Lisa K Stamp; Tony R Merriman; Nicola Dalbeth; Owen M Woodward Journal: Nat Commun Date: 2020-06-02 Impact factor: 14.919